Free Trial

Entrada Therapeutics (TRDA) Short Interest Ratio & Short Volume

$15.13
+0.11 (+0.73%)
(As of 05/24/2024 04:00 PM ET)

Entrada Therapeutics Short Interest Data

Current Short Interest
1,720,000 shares
Previous Short Interest
1,750,000 shares
Change Vs. Previous Month
-1.71%
Dollar Volume Sold Short
$20.38 million
Short Interest Ratio
22.4 Days to Cover
Last Record Date
April 30, 2024
Outstanding Shares
33,760,000 shares
Float Size
18,020,000 shares
Short Percent of Float
9.54%
Today's Trading Volume
33,800 shares
Average Trading Volume
75,640 shares
Today's Volume Vs. Average
45%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Entrada Therapeutics ?

Sign up to receive the latest short interest report for Entrada Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

TRDA Short Interest Over Time

TRDA Days to Cover Over Time

TRDA Percentage of Float Shorted Over Time

Entrada Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
4/30/20241,720,000 shares $20.38 million -1.7%9.5%22.4 $11.85
4/15/20241,750,000 shares $22.56 million -1.1%9.7%23.2 $12.89
3/31/20241,770,000 shares $25.08 million -1.1%9.9%23.2 $14.17
3/15/20241,790,000 shares $22.88 million -1.1%10.1%22.9 $12.78
2/29/20241,810,000 shares $23.95 million No Change10.0%22 $13.23
2/15/20241,810,000 shares $27.19 million -1.1%10.0%20.6 $15.02
1/31/20241,830,000 shares $26.66 million +0.6%10.2%21.3 $14.57
1/15/20241,820,000 shares $29.79 million -1.1%10.1%21.8 $16.37
12/31/20231,840,000 shares $27.77 million +2.8%10.2%23.5 $15.09
12/15/20231,790,000 shares $24.93 million +0.6%10.0%25.1 $13.93
11/30/20231,780,000 shares $23.09 million +7.2%9.9%28.3 $12.97
11/15/20231,660,000 shares $27.12 million -3.5%9.3%30.4 $16.34
10/31/20231,720,000 shares $27.54 million +4.2%9.6%38.1 $16.01
10/15/20231,650,000 shares $21.62 million +5.1%9.3%37 $13.10
9/30/20231,570,000 shares $24.81 million +2.0%8.8%31.3 $15.80
9/15/20231,540,000 shares $25.61 million No Change8.6%26.1 $16.63
8/31/20231,540,000 shares $22.67 million -1.9%8.6%14.3 $14.72
8/15/20231,570,000 shares $25.10 million -1.3%8.8%14.2 $15.99
7/31/20231,590,000 shares $27.62 million -1.9%6.0%14.4 $17.37
7/15/20231,620,000 shares $26.45 million +1.3%6.1%14.6 $16.33
6/30/20231,600,000 shares $24.22 million +30.1%6.0%14.7 $15.14
6/15/20231,230,000 shares $17.75 million +2.5%4.6%12.3 $14.43
5/31/20231,200,000 shares $13.75 million +0.8%4.5%24.4 $11.46
5/15/20231,190,000 shares $15.23 million +6.3%6.7%26.3 $12.80
4/30/20231,120,000 shares $13.12 million No Change6.7%23.9 $11.71
4/15/20231,120,000 shares $19.32 million No Change6.7%24.2 $17.25
3/31/20231,120,000 shares $16.24 million +0.9%7.0%23.5 $14.50
3/15/20231,110,000 shares $15.11 million +0.9%6.7%21.3 $13.61
2/28/20231,100,000 shares $14.03 million -3.5%6.6%19.4 $12.75
2/15/20231,140,000 shares $12.36 million +0.9%6.9%18.9 $10.84
1/31/20231,130,000 shares $13.73 million -1.7%6.8%19.2 $12.15
1/15/20231,150,000 shares $15.77 million -2.5%6.9%17.2 $13.71
12/30/20221,180,000 shares $15.95 million +4.4%7.1%17.7 $13.52
12/15/20221,130,000 shares $22.83 million -1.7%6.8%17.3 $20.20
11/30/20221,150,000 shares $17.22 million No Change7.0%16.3 $14.97
11/15/20221,150,000 shares $20.65 million +6.5%7.0%17.3 $17.96
10/31/20221,080,000 shares $24.61 million No Change6.5%17.3 $22.79
10/15/20221,080,000 shares $16.75 million No Change6.5%20.1 $15.51
9/30/20221,080,000 shares $17.02 million -0.9%6.5%17.5 $15.76
9/15/20221,090,000 shares $15.74 million -1.8%6.6%12.4 $14.44
Who are Nvidia’s New Silent Partners? (Ad)

Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.

I call these Nvidia’s “Silent Partners.”
8/31/20221,110,000 shares $14.02 million -1.8%6.7%12.2 $12.63
8/15/20221,130,000 shares $14.46 million -7.4%6.8%12.5 $12.80
7/31/20221,220,000 shares $15.62 million -20.3%7.4%12.3 $12.80
7/15/20221,530,000 shares $16.59 million -5.6%9.3%15.2 $10.84
6/30/20221,620,000 shares $19.73 million -6.9%9.9%13.9 $12.18
6/15/20221,740,000 shares $15.96 million No Change10.6%15.5 $9.17
5/31/20221,740,000 shares $11.76 million -1.7%10.6%19.6 $6.76
5/15/20221,770,000 shares $10.51 million No Change10.8%19.3 $5.94
4/30/20221,770,000 shares $10.58 million -5.9%10.7%18.4 $5.98
4/15/20221,880,000 shares $15.23 million -21.3%11.4%19.8 $8.10
3/31/20222,390,000 shares $22.44 million +2.6%14.5%28.3 $9.39
3/15/20222,330,000 shares $20.92 million +3.1%14.1%22.8 $8.98
2/28/20222,260,000 shares $27.41 million +15.3%15.0%15.7 $12.13
2/15/20221,960,000 shares $26.07 million +2.1%13.0%12.8 $13.30
1/31/20221,920,000 shares $21.25 million +1.6%12.2%11.4 $11.07
1/15/20221,890,000 shares $16.33 million +12.5%11.3%8.8 $8.64
12/31/20211,680,000 shares $28.76 million No Change10.3%7.2 $17.12

TRDA Short Interest - Frequently Asked Questions

What is Entrada Therapeutics' current short interest?

Short interest is the volume of Entrada Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 1,720,000 shares of TRDA short. 9.54% of Entrada Therapeutics' shares are currently sold short. Learn More on Entrada Therapeutics' current short interest.

What is a good short interest ratio for Entrada Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TRDA shares currently have a short interest ratio of 22.0. Learn More on Entrada Therapeutics's short interest ratio.

What is a good short interest percentage for Entrada Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.54% of Entrada Therapeutics' floating shares are currently sold short.

Is Entrada Therapeutics' short interest increasing or decreasing?

Entrada Therapeutics saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 1,720,000 shares, a decline of 1.7% from the previous total of 1,750,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Entrada Therapeutics' float size?

Entrada Therapeutics currently has issued a total of 33,760,000 shares. Some of Entrada Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Entrada Therapeutics currently has a public float of 18,020,000 shares.

How does Entrada Therapeutics' short interest compare to its competitors?

9.54% of Entrada Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Entrada Therapeutics: Heron Therapeutics, Inc. (18.11%), Olema Pharmaceuticals, Inc. (15.02%), Astria Therapeutics, Inc. (10.24%), Larimar Therapeutics, Inc. (6.11%), Travere Therapeutics, Inc. (16.83%), SIGA Technologies, Inc. (13.53%), COMPASS Pathways plc (4.99%), IGM Biosciences, Inc. (29.87%), KalVista Pharmaceuticals, Inc. (13.13%), Altimmune, Inc. (31.47%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

What does it mean to sell short Entrada Therapeutics stock?

Short selling TRDA is an investing strategy that aims to generate trading profit from Entrada Therapeutics as its price is falling. TRDA shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Entrada Therapeutics?

A short squeeze for Entrada Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TRDA, which in turn drives the price of the stock up even further.

How often is Entrada Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TRDA, twice per month. The most recent reporting period available is April, 30 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:TRDA) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners